Laboratório de Antibióticos, Bioquímica e Modelagem Molecular (LABioMol)-Instituto de Biologia, Universidade Federal Fluminense, Niterói, RJ, Brazil.
J Atheroscler Thromb. 2010 Jul 30;17(7):730-9. doi: 10.5551/jat.3293. Epub 2010 Jun 2.
Platelets plays a central role in hemostatic processes and consequently are similarly involved in pathological processes, such as arterial thrombosis and atherosclerosis. Herein we described the synthesis, antiplatelet profile and structure-activity relationship (SAR) of a new series of N'-substitutedphenylmethylene-1H-pyrazolo[3,4-b]pyridine-carbohydrazide derivatives (3a-3k).
These compounds were synthesized in good yield and tested in platelet aggregation assays using collagen, ADP and arachidonic acid as agonists. We also performed a SAR studies using SPARTAN' 08 program, in silico ADMET screening and the Lipinski " rule of five " using Osiris Property Explorer and molinspiration on-line programs.
Interestingly, the new compounds were active against collagen and arachidonic acid (AA) with the two most actives compounds (3a and 3c - IC(50)=61 microM and 68 microM respectively) almost 5-fold more potent than aspirin (IC(50)=300 microM). These derivatives showed low theoretical toxicity risks in in silico ADMET screening and fulfilled the Lipinski rule of five, suggesting good oral biodisponibility.
This work showed carbohydrazide group as potential for designing new antiplatelets. On that purpose, 3a and 3c may act as prototypes to generate more efficient and safe molecules for treating thrombotic diseases.
血小板在止血过程中起着核心作用,因此同样参与动脉血栓形成和动脉粥样硬化等病理过程。在此,我们描述了一系列新型 N'-取代苯亚甲基-1H-吡唑并[3,4-b]吡啶-甲脒衍生物(3a-3k)的合成、抗血小板特性和构效关系(SAR)。
这些化合物以良好的产率合成,并在使用胶原、ADP 和花生四烯酸作为激动剂的血小板聚集测定中进行了测试。我们还使用 SPARTAN' 08 程序、虚拟 ADMET 筛选和 Osiris Property Explorer 和 molinspiration 在线程序的 Lipinski“五规则”进行了 SAR 研究。
有趣的是,这些新化合物对胶原和花生四烯酸(AA)具有活性,其中两种最有效的化合物(3a 和 3c-IC(50)分别为 61 μM 和 68 μM)的活性几乎是阿司匹林(IC(50)的 5 倍)=300 μM)。这些衍生物在虚拟 ADMET 筛选中显示出低理论毒性风险,并满足 Lipinski 五规则,表明良好的口服生物利用度。
这项工作表明, carbohydrazide 基团具有设计新型抗血小板药物的潜力。为此,3a 和 3c 可以作为原型,用于生成更有效和安全的治疗血栓性疾病的分子。